Biotech entity
clinical-trial is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention Psilocybin, the most common co-covered peer. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.4 for the same window.
Last mentioned: Jul 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention Psilocybin, the most common co-covered peer. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.4 for the same window. Their average consequence score of 7 runs above the beat's 6.3 for that window. This profile follows 2 Biotech stories mentioning Johns Hopkins University across the period from March 6, 2026 to March 10, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 71 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Johns Hopkins University. Shared-story counts are live from our verified record — not editorial picks.
Phase 3 Trials
Large-scale multi-site trials aim to provide definitive data for regulatory approval.
SAP Expansion
Canada amends the Special Access Program to include restricted psychedelic substances.
Regulatory Shift
Health Canada begins granting Section 56 exemptions for terminally ill patients.
Foundational Research
Johns Hopkins and NYU publish landmark studies on psilocybin for cancer-related distress.
A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy.
Emerging clinical research indicates that psilocybin-assisted therapy can significantly alleviate existential dread and depression in terminally ill patients. This development marks a potential paradigm shift in palliative care, moving beyond physical pain management to address deep-seated psychological trauma.
Johns Hopkins University is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
